Geron (GERN) investor relations material

Commercial performance and market strategy

• RYTELO, a first-in-class telomerase inhibitor for low-risk MDS, achieved $47.2 million in U.S. net sales in the last reported quarter, with five quarters since launch.

• Uptake has been modest despite strong clinical data, attributed to initial focus on later-line patients and lack of U.S. trial familiarity among prescribers.

• Efforts are underway to shift adoption to second-line patients, aligning with pivotal trial design and recent NCCN guideline updates that position RYTELO ahead of HMAs.

• Key opinion leader (KOL) engagement is being strengthened, with increased outreach and tailored messaging to both academic and community physicians.

• Metrics such as new account openings, increased use in earlier lines, and academic engagement are tracked as leading indicators of growth.

Clinical data and physician engagement

• IMerge study data supports durable transfusion independence and robust response in second-line MDS patients.

• Academic centers are now conducting their own studies with RYTELO, leading to increased podium presence and peer advocacy.

• Community physicians require simplified messaging and support to manage side effects, especially cytopenias, to ensure continued therapy.

• Recent presentations highlight RYTELO's efficacy in improving survival, PFS, and reducing AML conversion, with cytopenia correlating to best response.

Pipeline and future growth

• The IMpactMF phase 3 trial in myelofibrosis is fully enrolled, with interim analysis expected in H2 2026 and full analysis in H2 2028.

• The trial aims to demonstrate survival benefit, potentially doubling the addressable patient market.

• RYTELO's coexistence with Luspatercept in the treatment landscape is expected to drive second-line uptake as more patients relapse from first-line therapy.